| Title: | ADRA2A and IRX1 are putative risk genes for Raynaud's phenomenon |
| Journal: | Nature Communications |
| Published: | 12 Oct 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37828025/ |
| DOI: | https://doi.org/10.1038/s41467-023-41876-5 |
| URL: | https://www.nature.com/articles/s41467-023-41876-5.pdf |
| Citations: | 7 (7 in last 2 years) as of 8 Aug 2024 |
Publication 9387
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Raynaud's phenomenon (RP) is a common vasospastic disorder that causes severe pain and ulcers, but despite its high reported heritability, no causal genes have been robustly identified. We conducted a genome-wide association study including 5,147 RP cases and 439,294 controls, based on diagnoses from electronic health records, and identified three unreported genomic regions associated with the risk of RP (p < 5 × 10−8). We prioritized ADRA2A (rs7090046, odds ratio (OR) per allele: 1.26; 95%-CI: 1.20-1.31; p < 9.6 × 10−27) and IRX1 (rs12653958, OR: 1.17; 95%-CI: 1.12-1.22, p < 4.8 × 10−13) as candidate causal genes through integration of gene expression in disease relevant tissues. We further identified a likely causal detrimental effect of low fasting glucose levels on RP risk (rG = −0.21; p-value = 2.3 × 10−3), and systematically highlighted drug repurposing opportunities, like the antidepressant mirtazapine. Our results provide the first robust evidence for a strong genetic contribution to RP and highlight a so far underrated role of α2A-adrenoreceptor signalling, encoded at ADRA2A, as a possible mechanism for hypersensitivity to catecholamine-induced vasospasms.</p>
10 Authors
- Sylvia Hartmann
- Summaira Yasmeen
- Benjamin M. Jacobs
- Spiros Denaxas
- Munir Pirmohamed
- Eric R. Gamazon
- Mark J. Caulfield
- Harry Hemingway
- Maik Pietzner
- Claudia Langenberg
1 Application
| Application ID | Title |
|---|---|
| 44448 | The genetic and environmental determinants of cardiometabolic and related disorders. |
Enabling scientific discoveries that improve human health